Antibody Engineering

Methods and Protocols, Second Edition

  • Patrick Chames

Part of the Methods in Molecular Biology book series (MIMB, volume 907)

Table of contents

  1. Front Matter
    Pages i-xvi
  2. In Silico Methods

    1. Front Matter
      Pages 1-1
    2. Marie-Paule Lefranc, François Ehrenmann, Chantal Ginestoux, Véronique Giudicelli, Patrice Duroux
      Pages 3-37
  3. Generation of Diversity

    1. Front Matter
      Pages 57-57
    2. Sylvie Peraldi-Roux
      Pages 73-83
    3. Michael Hust, André Frenzel, Torsten Meyer, Thomas Schirrmann, Stefan Dübel
      Pages 85-107
    4. Gautier Robin, Pierre Martineau
      Pages 109-122
    5. Eeva-Christine Brockmann
      Pages 123-144
    6. Cécile Vincke, Carlos Gutiérrez, Ulrich Wernery, Nick Devoogdt, Gholamreza Hassanzadeh-Ghassabeh, Serge Muyldermans
      Pages 145-176
    7. Mischa Roland Müller, Ronan O’Dwyer, Marina Kovaleva, Fiona Rudkin, Helen Dooley, Caroline Jane Barelle
      Pages 177-194
    8. Romain Rouet, Kip Dudgeon, Daniel Christ
      Pages 195-209
  4. Selections of Lead Candidate

    1. Front Matter
      Pages 211-211
    2. Julie Matz, Patrick Chames
      Pages 213-224
    3. Klervi Even-Desrumeaux, Patrick Chames
      Pages 225-235
    4. Sang Jick Kim, Hyo Jeong Hong
      Pages 247-257
    5. Nathalie Scholler
      Pages 259-280
    6. Bryan M. Edwards, Mingyue He
      Pages 281-292
    7. Chen Zhou, Wenyan David Shen
      Pages 293-302
  5. Production of Recombinant Antibodies

    1. Front Matter
      Pages 303-303
    2. Tomohisa Katsuda, Hiroyuki Sonoda, Yoichi Kumada, Hideki Yamaji
      Pages 305-324
    3. Steve Schoonooghe, Jannick Leoen, Jurgen Haustraete
      Pages 325-340
    4. Richard Yi Zhang, Wenyan David Shen
      Pages 341-358
    5. Daniel X. Johansson, Thomas Krey, Oskar Andersson
      Pages 359-370
    6. Takanori Furuta, Takafumi Ogawa, Hideki Yamaji
      Pages 371-387
    7. Freydoun Garabagi, Michael D. McLean, J. Christopher Hall
      Pages 389-408
  6. Variable Domain Optimization

    1. Front Matter
      Pages 409-409
    2. Stephen Hearty, Paul Leonard, Richard O’Kennedy
      Pages 411-442
    3. Klervi Even-Desrumeaux, Patrick Chames
      Pages 443-449
    4. Laurence Renaut, Céline Monnet, Olivier Dubreuil, Ouafa Zaki, Fabien Crozet, Khalil Bouayadi et al.
      Pages 451-461
    5. Rodrigo Barderas, Johan Desmet, Philippe Alard, J. Ignacio Casal
      Pages 463-486
    6. Alfredo Darmanin-Sheehan, William James Jonathan Finlay, Orla Cunningham, Brian Joseph Fennell
      Pages 487-503
  7. Fc Engineering

    1. Front Matter
      Pages 505-505
    2. Christiane Ogorek, Ingo Jordan, Volker Sandig, Hans Henning von Horsten
      Pages 507-517
    3. Stefanie Derer, Christian Kellner, Sven Berger, Thomas Valerius, Matthias Peipp
      Pages 519-536
    4. Axel Hernandez, Julie Parmentier, Youzhen Wang, Jane Cheng, Gadi Gazit Bornstein
      Pages 557-594
  8. Innovative Formats

    1. Front Matter
      Pages 595-595
    2. Andrea Fick, Agnes Wyzgol, Harald Wajant
      Pages 597-609
    3. Andreas A. Hombach, Hinrich Abken
      Pages 611-626
    4. Eleanor J. Cheadle, Vicky Sheard, Andreas A. Hombach, Markus Chmielewski, Tobias Riet, Cor Berrevoets et al.
      Pages 645-666
    5. Sandrine Moutel, Clément Nizak, Franck Perez
      Pages 667-679
    6. Jacques Barbet, Manuel Bardiès, Mickael Bourgeois, Jean-François Chatal, Michel Chérel, François Davodeau et al.
      Pages 681-697
    7. Glenn A. Powers, Peter J. Hudson, Michael P. Wheatcroft
      Pages 699-712
    8. Nora Hornig, Aline Färber-Schwarz
      Pages 713-727
  9. Back Matter
    Pages 729-734

About this book


More than ever, antibodies are being recognized as a major drug modality in a variety of diseases, including cancer, autoimmune diseases, infectious diseases, or even neurodegenerative disorders. Over 30 therapeutic antibodies have been approved and novel molecules are entering clinical trials at an average rate of 50 per year and that is predicted to continue well into the future. Notwithstanding the many achievements already made in the field, there is still a lot of room for improvements for these molecules in terms of activity, and a plethora of approaches have been attempted to optimize these molecules. Antibody Engineering: Methods and Protocols, Second Edition was compiled to give complete and easy access to a variety of antibody engineering techniques, starting from the creation of antibody repertoires and efficient ways to select binders from these repertoires, to their production in various hosts, their detailed characterization using various well established techniques, and to the modification and optimization of these lead molecules in terms of binding activity, specificity, size, shape, and more. Written in the successful Methods in Molecular Biology™ series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and notes on troubleshooting and avoiding known pitfalls.


Authoritative and easily accessible, Antibody Engineering: Methods and Protocols, Second Edition serves as an invaluable resource for both experts and those new to the field, and most of all as a source of inspiration for the creation of the antibodies of tomorrow.


Fc engineering antibody repertoires antibody variable domains in silico methods recombinant antibodies therapeutic antibodies

Editors and affiliations

  • Patrick Chames
    • 1
  1. 1.Antibody Therapeutics & ImmunotargetingINSERM U624Marseille CEDEX 09France

Bibliographic information

  • DOI
  • Copyright Information Springer Science+Business Media, LLC 2012
  • Publisher Name Humana Press, Totowa, NJ
  • eBook Packages Springer Protocols
  • Print ISBN 978-1-61779-973-0
  • Online ISBN 978-1-61779-974-7
  • Series Print ISSN 1064-3745
  • Series Online ISSN 1940-6029
  • Buy this book on publisher's site